文献速递神经肿瘤

孕激素相关脑膜瘤神经外科管理的23年单中心演变

Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience.
PubMed 文献 · J Neurooncol · 2021-01-15

结果显示孕激素相关脑膜瘤患者数量逐年增加,保守管理(包括停用孕激素)比例上升,且停用孕激素后保守管理的脑膜瘤中29.6%出现退缩、68.5%稳定、1.9%继续生长。

要点

  • 孕激素相关脑膜瘤患者数量随时间增加,2017年后年均22.0例。
  • 保守管理比例从2008年前的33.3%升至2017年后的64.3%。
  • 停用孕激素后保守管理的脑膜瘤多数稳定或退缩,仅1.9%继续生长。

核心结论

  • 孕激素相关脑膜瘤的保守管理(包括停用孕激素)随时间增加,在疗效和安全性方面结果良好。

研究设计与样本

  • 共纳入71例成年女性,125个孕激素相关脑膜瘤。

主要发现

  • 孕激素相关脑膜瘤患者数量随时间增加:2008年前每年0.5例,2017年后每年22.0例。
  • 孕激素治疗为批准适应症者占27.0%。
  • 每例患者平均发现1.7±1.2个脑膜瘤(中位数1,范围1-6)。
  • 36个(28.8%)脑膜瘤接受手术,病理分级WHO 1级占61.1%,2级占38.9%。
  • 保守管理比例从2008年前的33.3%升至2017年后的64.3%;停用孕激素比例从16.7%升至95.2%。

关键数值与推荐

  • 停用孕激素的比例因孕激素衍生物而异:醋酸环丙孕酮88.9%,醋酸氯地孕酮84.6%,醋酸诺美孕酮28.6%,孕激素衍生物联合66.7%。
  • 脑膜瘤治疗管理的主要原因是存在临床体征。
  • 54个保守管理且停用孕激素的脑膜瘤中,MRI随访显示29.6%退缩、68.5%稳定、1.9%继续生长。

临床怎么用

  • 对孕激素相关脑膜瘤患者,应考虑停用孕激素并采取保守管理,尤其是醋酸环丙孕酮和醋酸氯地孕酮相关者。
  • 保守管理期间需通过MRI随访监测脑膜瘤变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The improving knowledge of interactions between meningiomas and progestin refines the management of this specific condition. We assessed the changes over time of the management of progestin-associated meningiomas. METHODS: We retrospectively studied consecutive adult patients who had at least one meningioma in the context of progestin intake (October 1995-October 2018) in a tertiary adult Neurosurgical Center. RESULTS: 71 adult women with 125 progestin-associated meningiomas were included. The number of progestin-associated meningioma patients increased over time (0.5/year before 2008, 22.0/year after 2017). Progestin treatment was an approved indication in 27.0%. A mean of 1.7 ± 1.2 meningiomas were discovered per patient (median 1, range 1-6). Surgery was performed on 36 (28.8%) meningiomas and the histopathologic grading was WHO grade 1 in 61.1% and grade 2 in 38.9%. The conservative management of meningiomas increased over time (33.3% before 2008, 64.3% after 2017) and progestin treatment withdrawal increased over time (16.7% before 2008, 95.2% after 2017). Treatment withdrawal varied depending on the progestin derivative used (88.9% with cyproterone acetate, 84.6% with chlormadinone acetate, 28.6% with nomegestrol acetate, 66.7% with progestin derivative combination). The main reason for therapeutic management of meningiomas was the presence of clinical signs. Among the 54 meningiomas managed conservatively for which the progestin had been discontinued, MRI follow-up demonstrated a regression in 29.6%, a stability in 68.5%, and an ongoing growth in 1.9% of cases. CONCLUSIONS: Conservative management, including progestin treatment discontinuation, has grown over time with promising results in terms of efficacy and safety.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Malaize H, Samoyeau T, Zanello M, et al. Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience. J Neurooncol. 2021. PMID: 33449307. doi:10.1007/s11060-021-03696-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。